辉丰股份(002496) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥66,265,164.41, representing a decrease of 58.30% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥27,839,725.19, which is a 264.79% increase in loss compared to the previous year[5]. - The basic earnings per share were -¥0.0185, reflecting a 264.79% increase in loss compared to -¥0.0120 in the same period last year[5]. - The company recorded a loss of ¥41,400,260.42 after deducting non-recurring gains and losses, which is a 40.18% increase in loss compared to the previous year[5]. - The net profit for Q3 2022 was -94,287,267.67 CNY, a significant decline compared to a net profit of 504,574,026.34 CNY in the same period last year[30]. - Operating profit for Q3 2022 was -88,753,084.14 CNY, down from 586,627,873.49 CNY in Q3 2021[30]. - The company reported a total comprehensive income of -92,899,627.44 CNY for Q3 2022, compared to 306,092,720.32 CNY in Q3 2021[31]. - The basic and diluted earnings per share for Q3 2022 were both -0.0440 CNY, down from 0.3558 CNY in the previous year[31]. Revenue and Costs - The company reported a significant decrease in operating income, down 79% year-on-year to ¥203,046,883.34, primarily due to a reduction in the production and sales of original medicines and formulations following a major asset restructuring in May 2021[11]. - Total operating revenue for the period was CNY 203,046,883.34, a significant decrease from CNY 958,363,096.96 in the previous period, representing a decline of approximately 78.8%[29]. - Total operating costs amounted to CNY 278,430,091.62, down from CNY 1,086,940,213.94 in the previous period, indicating a reduction of about 74.3%[29]. Cash Flow and Assets - The net cash flow from operating activities was -¥13,280,280.62, indicating a 60.85% improvement compared to -¥19,846,276.53 in the previous year[5]. - The net cash flow from operating activities was negative at RMB -13,280,280.62, a 61% decline compared to RMB -8,256,295.75, driven by increased prepayment expenditures in trade business[12]. - The net cash flow from investing activities decreased by 82% to RMB 93,380,418.23 from RMB 509,605,414.32, primarily due to the receipt of equity transfer payments in the previous year[12]. - The net cash flow from financing activities improved by 95% to RMB -40,383,881.24 from RMB -760,298,853.54, as the company repaid bank loans and non-related party borrowings in the prior period[12]. - The company's cash and cash equivalents increased to CNY 194,693,419.11 from CNY 155,665,836.67, reflecting a growth of approximately 25%[25]. - Cash and cash equivalents at the end of Q3 2022 totaled 133,302,694.68 CNY, an increase from 78,729,166.42 CNY at the end of Q3 2021[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,675,746,320.73, a decrease of 2.35% from the previous year[5]. - Total assets as of September 30, 2022, were CNY 3,675,746,320.73, down from CNY 3,764,024,801.92 at the beginning of the year, indicating a decrease of about 2.4%[27]. - Total liabilities increased slightly to CNY 1,546,597,917.93 from CNY 1,543,377,061.48, reflecting a marginal increase of about 0.1%[27]. - The company's equity attributable to shareholders decreased to CNY 2,348,410,977.42 from CNY 2,411,882,951.96, a decline of approximately 2.6%[27]. - The company’s non-current assets totaled CNY 2,886,901,471.11, down from CNY 2,996,051,127.12, indicating a decrease of about 3.7%[26]. - The company’s total current liabilities increased to CNY 1,238,486,087.63 from CNY 1,204,148,121.23, representing an increase of approximately 2.8%[27]. Expenses - Management expenses decreased by 61% to RMB 92,861,875.40 from RMB 241,161,139.35, primarily due to the reduction in pharmaceutical and formulation production and sales following a major asset restructuring completed in May 2021[12]. - R&D expenses plummeted by 92% to RMB 1,569,090.22 from RMB 20,833,795.06, attributed to decreased investment in pharmaceutical R&D after the asset restructuring[12]. - The company incurred financial expenses of 17,478,131.99 CNY in Q3 2022, compared to 13,819,607.29 CNY in the same period last year[30]. - The total investment income for Q3 2022 was 13,722,037.41 CNY, a decrease from 703,680,377.78 CNY in Q3 2021[30]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 44,445, with the largest shareholder, Zhang Hangen, holding 31.19% of the shares[14]. Legal and Regulatory Issues - The company is facing ongoing litigation related to asset disposals and shareholder agreements, with significant financial implications pending resolution[17][18].